Not so fast, Teva. Vifor wins a few more years of protection from a potential Velphoro generic
Weeks after snapping up the chronic kidney disease drug Velphoro in its $11.7 billion Vifor buyout, CSL pulled in a court win that gives it at least a few more years on the market without competition from Teva.
US District Judge Maryellen Noreika of Delaware ruled on Thursday that Teva’s generic candidate for Velphoro — which has yet to be approved — would infringe on a patent held by Vifor Fresenius Medical Care Renal Pharma (VFMCRP), which is now part of CSL Vifor.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.